Annexon, Inc. (NASDAQ:ANNX) Receives Average Rating of “Buy” from Brokerages

Annexon, Inc. (NASDAQ:ANNX) has earned an average recommendation of “Buy” from the six ratings firms that are presently covering the firm, MarketBeat reports. Six analysts have rated the stock with a buy recommendation. The average 1 year target price among analysts that have issued a report on the stock in the last year is $15.80.

Several equities research analysts have weighed in on the stock. Needham & Company LLC reaffirmed a “buy” rating and issued a $16.00 price target on shares of Annexon in a research note on Friday, November 15th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Annexon in a research note on Friday, November 15th. Finally, HC Wainwright reissued a “buy” rating and issued a $30.00 price objective on shares of Annexon in a research note on Tuesday, December 17th.

Hedge Funds Weigh In On Annexon

A number of hedge funds have recently added to or reduced their stakes in ANNX. Parkman Healthcare Partners LLC lifted its holdings in shares of Annexon by 0.5% in the third quarter. Parkman Healthcare Partners LLC now owns 328,613 shares of the company’s stock valued at $1,945,000 after purchasing an additional 1,768 shares in the last quarter. The Manufacturers Life Insurance Company lifted its stake in Annexon by 1.6% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 159,586 shares of the company’s stock valued at $945,000 after acquiring an additional 2,450 shares in the last quarter. GSA Capital Partners LLP boosted its holdings in Annexon by 10.7% during the 3rd quarter. GSA Capital Partners LLP now owns 34,581 shares of the company’s stock worth $205,000 after acquiring an additional 3,355 shares during the last quarter. MetLife Investment Management LLC grew its stake in shares of Annexon by 11.8% in the 3rd quarter. MetLife Investment Management LLC now owns 55,212 shares of the company’s stock worth $327,000 after acquiring an additional 5,814 shares in the last quarter. Finally, Creative Planning raised its holdings in shares of Annexon by 29.5% in the third quarter. Creative Planning now owns 34,779 shares of the company’s stock valued at $206,000 after purchasing an additional 7,914 shares during the last quarter.

Annexon Stock Down 2.6 %

NASDAQ:ANNX opened at $4.13 on Wednesday. Annexon has a twelve month low of $3.86 and a twelve month high of $8.40. The company has a fifty day moving average of $4.95 and a 200-day moving average of $5.91. The firm has a market capitalization of $440.22 million, a P/E ratio of -3.93 and a beta of 1.11.

Annexon Company Profile

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.